Can  ||| S:0 E:4 ||| MD
any  ||| S:4 E:8 ||| DT
heart  ||| S:8 E:14 ||| NN
be  ||| S:14 E:17 ||| VB
preconditioned ||| S:17 E:31 ||| NNS
?  ||| S:31 E:33 ||| .
Influence  ||| S:33 E:43 ||| NN
of  ||| S:43 E:46 ||| IN
aging  ||| S:46 E:52 ||| VBG
and  ||| S:52 E:56 ||| CC
comorbidities  ||| S:56 E:70 ||| NN
on  ||| S:70 E:73 ||| IN
cardioprotection  ||| S:73 E:90 ||| VBG
There  ||| S:90 E:96 ||| EX
is  ||| S:96 E:99 ||| VBZ
experimental  ||| S:99 E:112 ||| JJ
and  ||| S:112 E:116 ||| CC
clinical  ||| S:116 E:125 ||| JJ
evidence  ||| S:125 E:134 ||| NN
showing  ||| S:134 E:142 ||| VBG
that  ||| S:142 E:147 ||| IN
brief  ||| S:147 E:153 ||| JJ
episodes  ||| S:153 E:162 ||| NNS
of  ||| S:162 E:165 ||| IN
ischaemia  ||| S:165 E:175 ||| NN
and  ||| S:175 E:179 ||| CC
reperfusion  ||| S:179 E:191 ||| NNS
applied  ||| S:191 E:199 ||| VBD
either  ||| S:199 E:206 ||| RB
prior  ||| S:206 E:212 ||| RB
to  ||| S:212 E:215 ||| TO
prolonged  ||| S:215 E:225 ||| JJ
ischaemia  ||| S:225 E:235 ||| NNS
( ||| S:235 E:236 ||| -LRB-
ischaemic  ||| S:236 E:246 ||| FW
preconditioning ||| S:246 E:261 ||| FW
) ||| S:261 E:262 ||| -RRB-
,  ||| S:262 E:264 ||| ,
or  ||| S:264 E:267 ||| CC
at  ||| S:267 E:270 ||| IN
the  ||| S:270 E:274 ||| DT
onset  ||| S:274 E:280 ||| NN
of  ||| S:280 E:283 ||| IN
reperfusion  ||| S:283 E:295 ||| NNS
( ||| S:295 E:296 ||| -LRB-
postconditioning ||| S:296 E:312 ||| LS
)  ||| S:312 E:314 ||| -RRB-
have  ||| S:314 E:319 ||| VBP
the  ||| S:319 E:323 ||| DT
ability  ||| S:323 E:331 ||| NN
to  ||| S:331 E:334 ||| TO
protect  ||| S:334 E:342 ||| VB
the  ||| S:342 E:346 ||| DT
heart  ||| S:346 E:352 ||| NN
against  ||| S:352 E:360 ||| IN
ischaemic-reperfusion  ||| S:360 E:382 ||| JJ
injury ||| S:382 E:388 ||| NN
.  ||| S:388 E:390 ||| .
The  ||| S:390 E:394 ||| DT
aim  ||| S:394 E:398 ||| NN
of  ||| S:398 E:401 ||| IN
this  ||| S:401 E:406 ||| DT
review  ||| S:406 E:413 ||| NN
is  ||| S:413 E:416 ||| VBZ
to  ||| S:416 E:419 ||| TO
discuss  ||| S:419 E:427 ||| VB
whether  ||| S:427 E:435 ||| IN
this  ||| S:435 E:440 ||| DT
endogenous  ||| S:440 E:451 ||| JJ
protective  ||| S:451 E:462 ||| JJ
mechanism  ||| S:462 E:472 ||| NN
is  ||| S:472 E:475 ||| VBZ
effective  ||| S:475 E:485 ||| JJ
in  ||| S:485 E:488 ||| IN
the  ||| S:488 E:492 ||| DT
aging  ||| S:492 E:498 ||| JJ
heart  ||| S:498 E:504 ||| NN
and  ||| S:504 E:508 ||| CC
in  ||| S:508 E:511 ||| IN
patients  ||| S:511 E:520 ||| NNS
with  ||| S:520 E:525 ||| IN
co-morbidities ||| S:525 E:539 ||| JJ
.  ||| S:539 E:541 ||| .
